Computer Assisted Surgical Systems Market: Technological Breakthroughs by 2026

Computer assisted surgical systems are used for pre-operative planning, surgical navigation, and to assist surgery procedure. Computer assisted surgeries commonly uses surgical robots that mimics human arm and carry out surgical procedures by series of small incisions. The advantages of using computer assisted surgical systems include improved access, magnified vision, and stabilized implantation via smart instrumentation assisted by infra-red camera for navigation and software. The demand for computer assisted surgery is growing at a fast pace due to precision, miniaturization, less pain, and less healing time as compared to conventional surgical practices. Moreover, technological advancements in surgical robots is also boosting growth of computer assisted surgical systems market. The high cost and maintenance of system, and lack of skilled professionals are expected to hinder growth of computer assisted surgical systems market.

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1487

Computer assisted surgical systems market Taxonomy:

By Product Type

  • Surgical Navigation Systems
  • Surgical Robots
  • Surgical Planners & Stimulators

By Surgery Type

  • Gynecology Surgery
  • General Surgery
  • Urology Surgery
  • Cardiovascular Surgery
  • Neurosurgery
  • Orthopedic Surgery
  • Other Surgeries

By End Users

  • Hospitals
  • Ambulatory Surgical Centers
  • Emergency Clinics

Computer Assisted Surgical Systems Market Driver

Computer assisted surgeries are carried out with the help of surgical robotic arms, which facilitates the surgery via small incision and less tissue damage. Furthermore, accuracy and precision of computer assisted surgeries drive growth of computer assisted surgical systems market. Moreover, minimally invasive surgery lowers the cost of healthcare. For instance, the research studies conducted by Johns Hopkins suggests that minimally invasive procedures adopted by American hospitals saves around US$ 280 million to US$ 340 million per year spend for post-surgical complications occurred due to open surgery for appendix, colon, and lungs. According to the Health Research Funding report, around 400,000 robotic surgeries were performed in the U.S. in 2012 and had estimated around 25% increase in the rate of robotic surgery annually. Therefore, increasing use of surgical robots is expected to drive growth of computer assisted surgical systems market.

Computer assisted surgery is preferred over conventional surgical methods due to its advantages and advancements in technology. The focus of manufacturers of computer assisted surgical systems on upgrading the robotic instruments and its accessories with features like high resolution, precision, and flexibility of robotic device is expected to propel growth of computer assisted surgical systems market. Moreover, manufacturers are focusing on widening the applications of computer assisted surgical systems with the increasing advancements in surgical robotic systems. For instance, in 2018, Auris Surgical Robots, cleared FDA approval for Monarch, an Auris robotic endoscopy system, which can be used for diagnosing and treating lung cancer. Furthermore, the adoption of strategies such as merger and acquisition by manufacturers leads to the expansion of the market. For instance, in 2016, Zimmer Biomet acquired Medtech SA to enter the surgical robotics market.

Computer Assisted Surgical Systems Market Outlook

On the basis of region, computer assisted surgical systems market is segmented into North America, Latin America, Europe, Middle East, and Asia Pacific. North America accounts for dominant share in the global computer assisted surgical systems market, which is attributed by the technological advancements in the region, whereas Asia Pacific is expected to witness faster growth in computer assisted surgical system market over the forecast period due to increasing healthcare facilities and high rate of medical tourism in this region.

Computer Assisted Surgical Systems Market – Key Players

The major players of computer assisted surgical systems market include Intuitive surgical, Inc., Stryker Corporation, Mazor Robotics Ltd., Hansen Medical, Inc. (a subsidiary of Auris Surgical Robotics), Accuray Incorporated, Omnicell, Inc., Smith & nephew, and Zimmer Biomet.

Global Huntington’s Disease Treatment Market Summit to Showcase New Innovations from Leading Manufacturing and Pharmaceutical Experts 2026

Huntington’s disease, also known as Huntington’s chorea, is an autosomal dominant inherited rare disorder that causes progressive degeneration of nerve cell of brain leading to deterioration of a person’s physical and mental abilities. Huntington’s disease symptoms usually are detected at the age of 30–50 and gets worse over 10 to 25 year period from the onset of disease. Huntington’s disease is usually associated with movement disorders, cognitive disorders or psychiatric disorders. Ultimately, the individual becomes susceptible to pneumonia, heart failure or other complications causing death. Huntington’s disease is preliminary diagnosed by neurological examination, neuropsychological testing, psychiatric evaluation, genetic test, and brain imaging and functioning. The available Huntington’s disease treatment is symptomatic treatment, which involves use of drugs such as tetrabenazine, antidepressants, antipsychotic or mood-stabilizing. Additionally, psychotherapy, speech therapy, physical therapy, occupational therapy or lifestyle and home remedies plays important in improving life of the patient.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1479

Growth of the Huntington’s disease treatment market is driven by rising prevalence of disease and increasing R&D programs by institutes and universities. According to Huntington’s disease Society of America, there are approximately 30,000 symptomatic people in the U.S. and over 200,000 at-risk of inheriting the disease. Organization such as CHID Foundation, Hereditary Disease Foundation, Huntington’s Disease Society of America, and International Huntington Association aid in creating awareness among patients and their family, which is also expected to support growth of the Huntington’s disease treatment market. However, social stigma related to Huntington’s disease, stringent regulations related to drug approvals, and limited approved drug are factors expected to negatively affect growth of the Huntington’s disease treatment market.

Huntington’s disease Treatment Market Dynamics:

By Drug Type:

  • Tetrabenazine
  • Deutetrabenazine
  • Other Drug Type

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Huntington’s disease Treatment Market Driver:

Currently, Huntington’s disease has no cure, therefore, the treatment available in the market aid in slowing down degeneration of the neurons. Huntington’s disease treatment market is dominated by off-labeled drugs, which creates opportunity for key players, to develop new drugs. Austedo, a generic of deutetrabenazine by Teva Pharmaceutical Industries Ltd., received FDA approval in 2017 and became second FDA approved drug for Huntington’s disease after Xenazine. Furthermore, Laquinimod and Pridopidine are in Phase 2 clinical trials for the treatment of Huntington’s disease. Moreover, tetrabenazine is been studied by Lundbeck, in 2017, for its ability to reduce impulsiveness, depression, and suicidal tendencies for patients suffering from Huntington’s disease and it is in Phase 4 clinical trials. This increase in R&D activities and strong company pipelines are factors expected to fuel growth of the global Huntington’s disease treatment market.

Institutes and universities are focusing on research program to develop novel therapies such as cell and gene based therapies for the treatment of the disease. Reversing cell loss due to degeneration is most likely a target for Huntington’s disease treatment. Neurogenesis and regeneration of neurons are the novel therapies used for restoration or manipulation of neuron cell by using stem cell therapy. Another such approach is lowering Huntingtin protein production, which is leading cause of Huntington’s disease. For instance, IONIS HTT by Ionis Pharmaceuticals, Inc., in collaboration with Roche, targets reduced production of Huntingtin protein, a genetic cause for the disease, via antisense drug technology. IONIS HTT was in phase 1/2a as in 2015. Moreover, key players are also focusing on use of neurotropic factors or cell transplantation. Therefore, development of various new therapies for treatment of Huntington’s disease is expected to aid in growth of the market over the forecast period.

Valeant Pharmaceuticals International Inc., Alnylam Pharmaceuticals Inc., Ceregene Inc., Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer limited, Palobiofarma S.L, Omeros and Ipsen are the major players operating in Huntington’s disease treatment market.

Alzheimer’s Drugs Market to Witness Robust Expansion by 2026

The Alzheimer’s disease is one of the most prevalent neurodegenerative disease, which is associated proportionately with increased life expectancy worldwide. Patient suffers and encounters various behavioral change with dementia, as a primary symptoms, which gets worse as disease progress. It majorly affects people of age group 65 and above. Currently, there is no therapeutic cure available for Alzheimer’s disease, however, available drugs can lower symptoms or severity of the disease. Although many companies have invested in the development of new drug for Alzheimer’s disease, a very few molecules have shown a steady improvement in condition of patient and many of those investigational candidates failed to provide significant improvement in patients condition during phase three clinical trials.

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1373

Market Dynamics

Major factor fueling growth of the Alzheimer’s drugs market is large number of drugs in pipeline, which are expected to enter into market by 2022. According to the study published by Translational Research and Clinical Intervention in September 2017, there are 105 new drugs in pipeline, out of which 25 are in phase one, 52 in phase two and 28 are in phase three. These new products has novel approach such as immunotherapy to target amyloid beta, beta-site amyloid precursor protein cleaving enzyme 1 inhibitors, tau aggregation inhibitor, serotonin 5-HT6 receptor antagonist. Along with this there is an increase amount of collaboration amongst companies for developing drugs in joint effort, for instance in November 2017, Novartis and Amgen, along with the Banner Alzheimer’s Institute, announced a collaboration to assess potential of the BACE1 inhibitor CNP520 to  prevent or delay symptoms of Alzheimer’s disease. In 2016, AstraZeneca and Eli Lilly and Company entered into worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials, as a potential disease-modifying treatment for Alzheimer’s disease. These collaborations are expected to accelerate the development process and bring efficiency in entire arena of operations. However, failing of investigational candidate in late stage is expected to be a huge setback in the current Alzheimer’s drugs market, for instance in February 2017, an external data monitoring committee warned that Merck & Co. terminated study of Alzheimer’s candidate verubecestat due to potential failure in a Phase II/III study.

Key features of the study:

  • This report provides in-depth analysis of Alzheimer’s drugs market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global Alzheimer’s drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Large number of undiagnosed patient’s and revised diagnostic guidelines to propel growth for Alzheimer’s drugs market

People suffering from early stage of Alzheimer’s disease with some dementia do not have appropriate access to the healthcare infrastructure to diagnose and treat the disease. For instance according to World Alzheimer Report in 2016, only around 50% patients suffering from dementia undergo diagnosis. The rate of underdiagnoses is 10% in low and middle income economies, therefore, this is expected to propel growth of Alzheimer’s drugs market. As of 2011, there were no standard guidelines for diagnosis of disease. Currently, biomarker tests involving amount of beta-amyloid in the brain, which can be visualized in positron emission tomography imaging are under research to diagnosis develop treatment for Alzheimer’s disease. Currently, there is no curative therapy available for Alzheimer’s disease. However, drugs for Alzheimer’s therapy are in pipeline, which are expected to launch in near future, which in turn is propelling growth of Alzheimer’s disease therapeutics market.

Key players operating in Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other prominent players whose products are under clinical trials are Eli Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.

Ebola Vaccine Market to receive overwhelming hike in Revenues by 2026

Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus disease, symptomatic treatment such as maintaining electrolyte balance, imagining required oxygen level, and treating infectious condition might help in improving patient’s health. Most of vaccines to prevent Ebola virus disease are under different developmental stage.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1365

Increasing number of Ebola cases in affected regions and new vaccine development for this are expected to be factors driving growth of the market

Increasing mortality rates due to Ebola is expected to be a major factor for growth of the market. According to World Health Organization, in January 2018, around 50% people infected with EVD, have died. African countries such as Siberia, Sierra Leone, Guinea, Democratic Republic of Congo, Senegal, and Mali, Nigeria were affected with EVD. In 2014–16, outbreak in West African countries such as Siberia, Leone, and Guinea, lead to deaths of around 11,300 individuals. Some cases were observed during 2014–16 outbreak in the U.S., Spain, Italy, the U.K. among people that travelled to affected African countries and people who came in contact with infected patients. In May 2017, WHO declared outbreak of EVD in Democratic Republic of Congo. There is still fear about potential outbreak of EVC in vulnerable regions of Western Africa which earlier faced EVD outbreak due to gaps in public health infrastructure.Various institutes and pharmaceutical companies are focusing on developing vaccines against EVD.

According to study published in the journal, The Lancet, in December 2016, rVSV-ZEBOV also known as V920 vaccine, which is jointly developed by Newlink Genetics and Merck and Company, was found to be effective in protection against EVD in phase three trial. rVSV-ZEBOV uses strain of Zaire Ebola virus. Merck is planning to file for final marketing approval of its EVD vaccine with the U.S. FDA in 2018. Moreover, it produced 3,00,000 vaccines, in case of fresh outbreak in vulnerable regions. Various key players are focusing on developing vaccines for EVD, in order to expand its market share. For instance, GlaxoSmithKline developed CAd3-ZEBOV vaccine, derived from chimpanzee adenovirus and was tested by National Institute of Allergic and Infectious Disease, which started its phase three trials in February 2016. Janssen Pharmaceutical’s Ad26-ZEBOV is an experimental vaccine under development and currently in phase one. In 2014, Novavax Inc. developed Ebola vaccine by using its proprietary recombinant technology.

Ebola Vaccine Market Taxonomy:

On the basis of virus strain, the global Ebola vaccine market is segmented into:

  • Recombinant vesicular stomatitis virus-Zaire Ebola virus
  • Chimpanzee Adeno virus type 3-Zaire Ebola virus
  • Adeno virus serotype 26- Zaire Ebola Virus

In January 2018, GeoVax Labs Inc., published results tested in non-hamate primates for its experimental vaccine, GEO-EM01 against EVD. It is based on company’s novel Modified Vaccinia Ankara Virus like Particle (VLP) platform, which produces non-infectious VLPs in body of vaccinated individual. These VLP’S mimics the natural infection, which triggers the body to produce immune response with both antibodies and T cells.

GAVI is an international organization (global Vaccine Alliance) paid US$ 5 million to Merck & Company in 2016 for procurement of the vaccine (V 920 vaccine). Key players in the global Ebola vaccine market are Merck and Company, Janssen Pharmaceutica NV, GlaxoSmithKline, and Novavax Inc.

Insulin Delivery Devices Market Report Study, Synthesis and Summation 2018-2026

Direct subcutaneous insulin injection are the most common form of drug delivery, using a needle and syringe. There are different types of insulin delivery devices available including, syringes, pens, jet injectors, and insulin pumps. Insulin can be packaged in vials (bottles), cartridges or prefilled pens. However, several disposable and reusable pen devices have been developed that provide options for delivering rapid insulins and insulin premixes. Type or dosage of insulin can be changed according to the requirements to meet the individual needs of the patient Manufacturers are focusing on designing products, which are cost effective for people with diabetes which is expected to propel the growth of the insulin delivery devices market. For instance, in July 2017, Becton, Dickinson and Company launched BD Viva pen needles, have a highly engineered needle tip design for improved comfort and considered as the most cost-effective option for insulin-injecting people with diabetes in the UK.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1352

Market Dynamics

The market is gaining significant traction due to increasing prevalence of diabetes, and new innovations in terms of design. According to the World Health Organization, in 2016, an estimated 422 million adults are living with diabetes globally. The major spike in incidence of type 2 diabetes over the last decade is mainly attributed to rising prevalence of obesity. However, high cost of some insulin delivery devices is expected to be a restraining factor for the market growth. For instance, insulin analogs supplied in cartridges or prefilled pens have a higher per unit of insulin cost than insulin analogs supplied in vials. For example, one vial (1000 U) of insulin costs US$ 105.95, which equates to a cost of 10.6 cents per unit of insulin. Five prefilled insulin pens containing insulin glulisine (total of 1500 U) have a total cost of US$ 201.01, equating to a cost of 13.4 cents per unit of insulin (26% over the cost of insulin glulisine supplied in a vial).

Key features of the study:

  • This report provides in-depth analysis of the insulin delivery devices market and its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: (2017–2025), considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global insulin delivery devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans

Increasing adoption of advanced devices for insulin delivery is driving growth of the market

Increasing awareness among population regarding insulin delivery devices coupled with high demand for insulin administration for diabetes control are the factors driving growth of the market. Among region, North America, accounted for largest market share in insulin delivery devices, followed by Europe, owing to high prevalence of lifestyle associated diseases, implementation of awareness programs regarding diabetes, and high adoption of advanced medical devices. For instance, in 2010, according to Journal of Diabetes Science and Technology, majorly insulin pumps were used on the American side of the Atlantic than on the European side, which is projected to propel demand for insulin pumps over the forecast period.

Key players in the market are focusing on developing next generation devices to remain competitive, while seeking ways to enhance their design capabilities. For instance, in October 2017, Eli Lilly and Company announced its plans to invest US$ 72 million in an insulin manufacturing project at one of its Indianapolis facilities. The investment will be used to replace an existing insulin vial filling line and allow Lilly to meet growing demand for its insulins – including Humalog (insulin lispro) and Humulin (human insulin) – while upgrading to state-of-the-art technology and preparing for its insulin pipeline.

Rising Adoption of Healthcare in North America will Boost The Lab Automation Market Growth

Lab automation systems incorporates use of high end equipment’s and software into various laboratory procedure such as sample preparation with reagent mixing, pipetting out sample, performing sample analysis for characterization of the compound in the sample, sensitive lab ware movement, liquid dispensing assay performance, and cell culture preparation. Lab automation systems provides advantage such as precision in operations, saving time by performing batch operations, and accuracy of data due to minimizing human error. It also prevents sample wastage (in case sample having very low yield). Increasing applications of lab automation in research laboratory is creating potential opportunity for growth of the market.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1334

Market Dynamics

Major factor driving growth of the lab automation market include the need for accurate diagnosis in less time with minimum error. For instance, ELISA test is utilized in diagnosis of diseases such as Zika, AIDS, rotavirus, syphilis, and chickenpox. These diseases has high prevalence worldwide and frequent outbreaks of the same as infectious disease may promote use of automated ELISA systems. Increasing use of the DNA sample in diagnostics with tedious procedure involved in it is expected to propel growth of the lab automation market. Pharmaceutical companies worldwide are involved in genomics research, there is increasing research spending and collaboration with genomics firms by pharmaceutical and biotechnological companies in which lab automation will play crucial role. In April 2016, AstraZeneca launched project to sequence genome of over 2 million people by collaborating with biotech firm Human Longetivity, Inc., and other academic institutions. In March 2015, Genomics England announced to partner with 10 pharmaceutical and biotechnological companies to develop new diagnostics and treatments for cancer patient and rare disease, using the genomic sequences gathered through the 100,000 Genomes Project.

However, high cost associated with lab automation equipment is hindering growth of the market, as these equipment’s are costly to acquire by small research institutions reducing the wide adoption of the system.

Key features of the study:

  • This report provides in-depth analysis of lab automation market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global lab automation market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Pharmaceutical and biotech companies are focused on development of novel molecules for treatment of chronic disease such as cancer and cardiovascular disease, which require utilization of lab automation equipment, which in turn is expected to drive growth of the lab automation market. According to report published by International Federation of Pharmaceutical Manufacturer and Association in 2017, pharmaceutical industry invests US$ 149.8 billion on research and development annually. Furthermore, more than 7000 compounds are in preclinical stage of development out of which 56 were launched in 2015 and in 2011 – 2015 around 225 new chemical and biological entities were launched.

Increasing research and development in personalized medicine to drive growth of the lab automation market

Lab automation market is expected to gain significant traction in near future due to advancements in personalized medicine by utilizing tools of genome engineering. For instance, immuno-oncology utilizes CAR-T cell therapy for isolation of T cells from patients, which then genetically engineered to produce receptors on their surface called chimeric antigen receptors and such cells are multiplied by in vitro methods. Most of the steps involved in this procedure require lab automation equipment. For instance, automated liquid handling system would boost the assay and sample preparation of CAR-T cells, automated storage and retrieval system helps in efficient preservation and storage of original and multiplied T cells, which are to be administered in patient’s body.

Key players operating in the lab automation market include Tecan Group Ltd., PerkinElmer Inc., Danaher Corporation, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Hamilton Robotics, Abbot Diagnostics, Eppendorf, Roche Diagnostics, and Siemens Healthineers.

Disposable IV Therapy Products Market Set for Rapid Growth And Trend by 2026

Intravenous (IV) therapy products are used to treat a variety of conditions including dehydration and nutrient-absorption disorders. It is increasingly given at homecare and clinics to help patients feel better without clogging emergency departments. IV therapy is also commonly used as an essential part of treatment regimens by doctors and paramedics responding on air and land ambulances, chiefly in traumatic injury management.

Market Dynamics

The major factors driving growth of the disposable IV therapy products market is increasing patient volume including geriatric population base and rising incidence of chronic diseases. For instance, according to National Health Service, in 2016, patients aged 65 to 69 made up the largest age group of hospital admissions in UK. Demand for disposable IV therapy products will also experience upward momentum as clinics, hospitals, and other health care institutions adopt stringent infection prevention norms to meet standards set by the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO) and the Centers for Disease Control and Prevention (CDC). Advances in disposable IV therapy products technology is expected to have a positive impact on demand for disposable IV therapy products. Increasing introduction of novel and advanced products based on improved designs and materials is expected to drive growth of the market.

Download The PDF Brochure:  https://www.coherentmarketinsights.com/insight/request-pdf/1327

For instance, the disposable needleless connector marketed by SPECATH in 2013 is utilized as channels or injestion sites for need of IV infusion. Its particular design provides many advantages with consumers, such as convenient sterilization and no need of sealing catheter. Increasing application of infusion devices for relieving pain, growing attention towards healthcare infrastructure, and rising prevalence of chronic diseases is likely to propel the market growth.

Key features of the study:

  • This report provides in-depth analysis of disposable IV therapy products market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global disposable IV therapy products market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Detailed Segmentation:

  • Global Disposable IV Therapy Products Market, By Product Type:
    • Intravenous Sets
    • Infusion Pumps
    • Needleless Connectors
    • Other Products
  • Global Disposable IV Therapy Products Market, By End User:
    • Hospitals
    • Clinics
    • Home Healthcare
  • Global Disposable IV Therapy Products Market, By Geography:

Technological advancements in IV therapy products to accelerate the market growth

Growing focus on cost containment and cost effectiveness at health care facilities coupled with technological advances in IV therapy products have allowed the effective and safe use of IV therapies. Increasing inclination of patients towards safety-enhancing pumping instruments and needleless technologies are expected to drive growth of the disposable IV therapy products market over the forecast period. For instance, in 2014 CareFusion (a Becton Dickinson subsidiary) launched MaxZero needleless connector (zero reflux connector) that offers the same technology as the MaxPlus connector, designed to reduce the risk of occlusions and infections.

The major players operating the global disposable IV therapy products market include B. Braun Melsungen AG, Baxter, Beckton Dickinson & Company, Caesarea Medical Electronics, ICU Medical, Inc., JMS Co. Ltd., Lily Medical Corporation, Smiths Medical, and Terumo Corporation.

Surgical Staplers Market predicts rise in demand by 2026

Surgical stapler is used to close wounds, including skin incisions and bowel resections in surgical settings. It can be either reusable (made of stainless steel) or disposable (made of plastic). Disposable staplers are tailored with disposable cartridges and used on single patient, while reusable staplers can be reloaded with disposable cartridges. The stapler can be used again after sterilization. The use of surgical staplers offers efficient wound closure, faster recovery, higher accuracy, and reduced hospital stay.

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1318

Market Dynamics

The major factors driving growth of the surgical staplers market include rising geriatric population and increasing prevalence of obesity requiring surgical procedures. Bariatric surgery is a group of surgical weight loss procedures aimed to help obese people. As the prevalence of obesity is growing, there is also a proportionate surge in the number of people undergoing weight loss surgeries. For instance, according to the American Society for Metabolic and Bariatric surgery report 2016, the total number of bariatric surgery completed in the U.S. in year 2011 was 158,000. Technological advancements have led to development of various unique surgical instruments and devices. For instance, the MicroCutter 5/80 launched by Dextera Surgical Inc. in 2016, is the world’s first and only 5mm surgical stapler that articulates to 80 degrees in each direction. Introduction of new products and continuing technical developments in existing products are changing the way conventional surgeries are performed. However, strict regulatory landscape, high associated cost, and wide availability of alternative techniques such as sutures can hamper the market growth.

Key features of the study:

  • This report provides in-depth analysis of surgical staplers market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global surgical staplers market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Increasing number of surgeries to augment market growth

Increasing number of surgical procedures demanding surgical staplers is expected to be a major factor driving the global surgical staplers market over the forecast period. Staples are commonly used in surgical specialties such as cardiothoracic, gynecological, gastrointestinal, head, orthopedic, hand, urologic and vascular surgery. With an increase in chronic non-communicable disorders such as thoracic and cardiac diseases, there is a simultaneous rise in associated interventions required to treat these disorders.

Increasing preference for surgical staplers over sutures to accelerate the market growth

Stapling involves minimal skin penetration in comparison to stitches and are preferred due to their ease of use, rapidity of application and are less prone to infection. Staples are less likely to cause negative skin reactions than suturing materials since they are made of stainless steel. According to a study reported in International Surgery Journal 2017, the use of stapling to close skin incision in laparotomy cases lessens surgical site infection, reduces the pain experienced by the patient and leaves lesser scars.

The major players operating in the global surgical staplers market include B. BRAUN MELSUNGEN AG, CONMED Corporation, Dextera Surgical Inc., Frankenman International Ltd., Grena Ltd., Intuitive Surgical Inc., Johnson & Johnson, Medtronic Plc, Purple Surgical and Surkon Medical.

Breast Implants Market Scrutinized in New Research

Breast implants are prosthesis that are intended for modifying or enhancing the size, shape, and contour of breasts. These devices are mainly used in reconstructive plastic surgery or cosmetic surgical procedures to restore the natural look of breasts, usually after mastectomy or breast cancer treatment that leads to congenital defects and deformities in the breasts. Breasts implants are implanted using a procedure known as breast augmentation.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1309

Market Dynamics

Major factor driving growth of the breast implants market is increasing consumer inclination towards breast enhancement for improving aesthetic appeal through cosmetic surgeries. According to American Society of Plastic Surgeons, 2016, around 99,614 breast lift surgeries were performed in the U.S. in 2015, witnessing a rise of 89% since 2000. Moreover, the AASPS, 2016, also suggested that breast augmentation was the most frequently performed cosmetic surgery in the U.S. with over 270,000 procedures performed in 2015. Additionally, rising incidence of breast cancer is also one of the major factors for which females undergo breast implant surgeries after breast removal procedures. This helps women in attaining the natural shape of their breasts. According to Cancer Research UK, 2016, breast cancer accounted for almost 15% of total cancer cases in the U.K. in 2015. However, risk factors such as deflation and capsular contracture of the implants are expected to be factors hindering the market growth.

Key features of the study:

  • This report provides in-depth analysis of breast implants market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017–2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global breast implants market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans

Increasing awareness regarding one’s aesthetics is expected to be major factor for fuelling the market growth

Breast implantation surgery is majorly performed on women to enhance their physical appearance. Reconstruction includes surgical treatments for breasts, to make them look appealing and youthful. Breast implantation procedures are also performed after mastectomy or patients treated with breast cancer to increase aesthetic appeal. According to the American Society of Plastic Surgeons (ASPS), 2015, nearly 100,000 breast implantation procedures were conducted in the U.S. and this number is expected to increase significantly. North America is expected to be dominant in the breast implants market, owing to increasing number of cosmetic procedures performed annually, rising number of clinics, and wide availability of skilled specialists.

Advancements in technology and launching of new innovative products is another factor driving market growth

A number of leading and new players are focusing on research and development to incorporate various new technologies, in order to overcome issues associated with existing implants. For instance, in September 2016, Allergen received U.S. FDA approval to market NATRELLE INSPIRA — a cohesive breast implant as its newest category into gummy implants —to increase breast fullness. NATRELLE is the advanced version of the company’s existing implant INSPIRA that was introduced in December 2011 as a round gel filled breast implant.

Major players operating in the global breast implants market include Allergen, Inc., Mentor Worldwide LLC, GC Aesthetics Plc, Sientra, Inc., POLYTECH Health and Aesthetics GmBH, Establishment Labs S.A., LABORATORIES ARION, HANSBIOMED Co. Ltd., Groupe Sebbin SAS, and GG Biotechnology Ltd.

Respiratory Devices Market: Business Planning Research, Reviews & Comparison of Alternatives

Respiratory devices or equipment are commonly used in the medical settings as per the medical condition. Ventilators are the most common tools, which are commonly used in emergency medicine and long-term critical care. In addition to the therapeutic respiratory devices, the diagnostic and monitoring devices minimize hospitalizations, thereby lowering the cost associated with medical settings.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1299

Market Dynamics

The major factor driving growth of the respiratory devices market include INCREASING prevalence of respiratory diseases such as COPD and asthma, increasing respiratory disease with rise in pollution level and rising geriatric population. According to the study by Global Burden of Disease, 2016, an estimated around 251 million cases of COPD were reported worldwide. According to the World Health Organization (WHO), 2015, an estimated 3.17 million deaths were caused by the disease accounting for 5% of all deaths. However, lack of awareness regarding the diseases harmful effects of certain respiratory care devices on neonates are the factors restraining respiratory devices market growth.

Key features of the study:

  • This report provides in-depth analysis of respiratory devices market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global respiratory devices market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Increasing admissions of critical care patients in Intensive Care Units (ICU) is expected to fuel the market growth

Increasing prevalence of chronic respiratory diseases such as asthma, chronic pulmonary lung disease, pulmonary hypertension, and occupational lung disease are the major factors augmenting growth of the respiratory devices market, owing to the pronounced need of therapeutic respiratory devices in the medical as well as in the homecare settings. According to the World Health Organization (WHO), in 2017, asthma is a major non communicable disease with an estimated 235 million people suffering from the condition.

Increasing support from international organizations for prevention of chronic respiratory diseases is expected to accelerate the market growth

Various organizations, institutions, and agencies are working towards improving the diagnosis and the medical care needed to reduce the global burden of respiratory diseases. For instance, the Global Alliance against Chronic Respiratory Diseases (GARD) was formed with the support from the World Health Organization (WHO) to control chronic respiratory diseases. GARD is a voluntary alliance of national, international organizations, and agencies from many economies. The main objective of GARD is to develop simple and affordable strategies for chronic respiratory diseases (CRD) and to encourage economies to implement health promotion and CRD prevention policies.

The major players operating the global respiratory devices market include Koninklijke Philips N.V., 3M, AstraZeneca Plc., GE Healthcare, GlaxoSmithKline Plc., Medtronic plc, Becton, Dickinson and Company, Invacare Corporation, ResMed, Inc., and CareFusion Corporation.